Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Curr Opin HIV AIDS. 2013 Jul;8(4):255–261. doi: 10.1097/COH.0b013e328361cee8

Table 3.

Opportunities provided by the NHP models in studies of HIV eradication

  1. Identity, dose, and route of virus challenge known.

  2. Control for various clinical parameters that are virtually impossible to control in humans (time of infection, duration of ART etc).

  3. Comprehensive cellular and anatomic characterization of both active and persistent reservoirs (including elective necropsy).

  4. Pilot trials of in vivo eradication conducted in a timely and controlled fashion; treatment interruption is possible.

  5. Testing of “risky” interventions (i.e., cell depletion experiments, stem cell-based interventions etc).